Healthcare Industry News: migraine
News Release - May 7, 2007
ProEthic Names James R. Lattanzi Chief Financial OfficerAccomplished Financial Executive Brings Wealth of Industry Expertise to Emerging Specialty Pharmaceutical Company
MONTGOMERY, Ala.--(HSMN NewsFeed)--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses, and markets niche prescription products, today announced the appointment of James R. Lattanzi as the company's chief financial officer. Mr. Lattanzi brings over 30 years of financial and business experience to ProEthic, including leadership positions at King Pharmaceuticals, Inc. and PricewaterhouseCoopers LLP.
"Jim joins ProEthic with an impressive array of skills and expertise in finance, accounting and infrastructure expansion," stated Carl Whatley, chairman and CEO of ProEthic Pharmaceuticals, Inc. "His knowledge and success in the pharmaceutical industry will be a particularly valuable asset to our organization as we work to advance our key business objectives."
Prior to his appointment at ProEthic, Mr. Lattanzi spent approximately five years (2000-2005) at King Pharmaceuticals, serving as the company's chief financial officer. During his tenure as CFO, he played a leading role in implementing the company's aggressive acquisition strategy, which required capital, due diligence, integration, systems upgrades and building a first class finance organization. Recently, Mr. Lattanzi served as a consultant with King while pursuing a post-graduate degree.
Prior to his tenure at King Pharmaceuticals, Mr. Lattanzi spent twenty-four years (eleven as a partner) at PricewaterhouseCoopers LLP, and its predecessor, Coopers & Lybrand LLP, primarily as a client service partner in the firm's Pittsburgh, PA, New York, NY and Greensboro, NC offices. At the time of his departure from the firm, he served as managing partner of the firm's Greensboro, NC office, helping establish it as a significant growth office of the firm with over 50 professionals.
Mr. Lattanzi received his MBA from Wake Forest University in December 2006 and his bachelor of science in accounting from Indiana University of Pennsylvania. He is a Certified Public Accountant and a member of several professional societies, including the American Institute of Certified Public Accountants and Financial Executives International.
About ProEthic Pharmaceuticals, Inc.
ProEthic is an emerging specialty pharmaceutical company enhancing treatment strategies initially in the areas of pain and migraine. Founded in 2001, the privately held company focuses its efforts on the acquisition, development, licensing, and marketing of pharmaceutical products. ProEthic also markets niche generic prescription pharmaceutical products through Midlothian Laboratories LLC, a wholly owned subsidiary. For more information, please visit the ProEthic website at: www.proethic.com.
Source: ProEthic Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.